Biogen spins off Bioverativ with focus on hemophilia

Biogen shareholders automatically received stock in Bioverativ.  
Biogen shareholders automatically received stock in Bioverativ.   | File photo
Biogen Inc., a global pharmaceutical manufacture, has launched a subsidiary global hemophilia business, Bioverativ.
Bioverativ is an independent, publicly traded company focused on hemophilia and rare blood disorders.
The separation occurred on Feb. 1 with stock shares available for purchase on Feb. 2. Biogen shareholders automatically received stock in Bioverativ.  
Want to get notified whenever we write about Biogen ?
Next time we write about Biogen, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Biogen 225 Binney St Cambridge, MA - 02142